Endologix submits premarket approval application to FDA for Detour system

Endologix has announced the submission of a premarket approval (PMA) application requesting approval for the Detour system to the US Food and Drug Administration (FDA). The Detour system, which earned FDA Breakthrough Device Designation, is a unique therapy that allows the creation of a fully percutaneous femoropopliteal bypass that is routed through the femoral vein. […]

The post Endologix submits premarket approval application to FDA for Detour system appeared first on Vascular News.